Cargando…
Assessment of the availability of repurposed orphan drugs in India
India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India’s patent regime p...
Autores principales: | Rajueni, Khujith, Chakraborty Choudhury, Mohua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529578/ https://www.ncbi.nlm.nih.gov/pubmed/37756282 http://dx.doi.org/10.1371/journal.pgph.0001498 |
Ejemplares similares
-
Rare disease patients in India are rarely involved in international orphan drug trials
por: Chakraborty, Monoswi, et al.
Publicado: (2022) -
The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2019) -
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2022) -
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis
por: Sterkel, Marcos, et al.
Publicado: (2021) -
The role of patient organizations in the rare disease ecosystem in India: an interview based study
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2019)